LGD-4033

LGD-4033

Systematic (IUPAC) name
4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Clinical data
Routes of administration	Oral
Legal status	Investigational new drug
Pharmacokinetic data
Biological half-life	24-36 hours [1]
Identifiers
CAS Number	1165910-22-4
ATC code	None
PubChem	CID 44137686
UNII	1EJT54415A
Chemical data
Formula	C14H12F6N2O
Molar mass	338.25 g·mol^−1
SMILES FC([C@H](O)[C@H]1CCCN1C2=CC(=C(C#N)C=C2)C(F)(F)F)(F)F
InChI InChI=1S/C14H12F6N2O/c15-13(16,17)10-6-9(4-3-8(10)7-21)22-5-1-2-11(22)12(23)14(18,19)20/h3-4,6,11-12,23H,1-2,5H2/t11-,12-/m1/s1 Key:OPSIVAKKLQRWKC-VXGBXAGGSA-N

LGD-4033 (now known as VK5211)^[2] is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics.^[3][4]

References

1. Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, et al. (Jan 2013). "The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.". J Gerontol A Biol Sci Med Sci 68: 87–95. doi:10.1093/gerona/gls078. PMID 22459616.
2. VK5211 on BioCentury
3. "Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting" (Press release). San Diego: Ligand Pharmaceuticals. November 20, 2009. Retrieved November 23, 2014.
4. Viking Signs Broad Licensing Deal With Ligand Pharmaceuticals for Rights to Five Novel Therapeutic Programs